Chronic treatment with fluoxetine for more than 6 weeks decreases neurogenesis in the subventricular zone of adult mice

Koji Ohira1,2, Tsuyoshi Miyakawa1,2,3*

Abstract

Background: Recent studies indicate that chronic treatment with serotonergic antidepressants upregulates adult neurogenesis of the dentate gyrus (DG). In contrast, some studies claimed that there was very little alteration of neurogenesis in the subventricular zone (SVZ) by the antidepressants. Since almost all of those studies treated animals with drugs for 2 to 4 weeks as chronic treatment models of antidepressants, it is possible that antidepressant treatments for longer periods would affect adult neurogenesis in the SVZ.

Results: In the present study, we examined the effects of long-term (up to 9 weeks) administration of fluoxetine (FLX), a selective serotonin reuptake inhibitor, on cell proliferation and survival in the DG and the SVZ of adult mice. As reported previously, in the DG of mice treated with FLX for 3, 6, or 9 weeks that were also injected with 5-bromodeoxyuridine (BrdU) in the last 3 days before perfusion, the numbers of Ki67- and BrdU-positive cells, which are cell proliferation markers, were significantly upregulated even at 3 weeks after the onset of the FLX treatments, and these increases were sustained in mice treated with FLX for 9 weeks. On the other hand, in the SVZ, we found a small, insignificant decrease in the numbers of Ki67- and BrdU-positive cells at 3 weeks, followed by highly significant decreases in the numbers of Ki67- and BrdU-positive cells at both 6 and 9 weeks. Furthermore, among olfactory newly generated cells that survived for 3 weeks after BrdU injection, the number of new cells was decreased at 9 weeks of FLX treatment.

Conclusions: These results demonstrate that long-term (more than 6 weeks) treatment with FLX has the opposite effect on neurogenesis in the SVZ than it does in the DG. The results also suggest that the decrease in neurogenesis in the SVZ might be involved in some aspects of the drug's therapeutic effects on depression. In addition, our findings raise the possibility that some of the side effects of antidepressants might be mediated by decreased adult neurogenesis in the SVZ.

Background

It has been accepted that adult neurogenesis occurs in two regions, the hippocampal dentate gyrus (DG) and the anterior subventricular zone (SVZ), of the healthy adult mammalian brain throughout life [1]. Currently, a variety of factors that can modulate neurogenesis in these regions have been identified: drugs [2], exercise [3], environmental enrichment [4], pregnancy [5], and stroke upregulate neurogenesis [6], whereas stress [7] and aging [8] downregulate it.

Among the drugs that modulate adult neurogenesis, selective serotonin reuptake inhibitors (SSRIs) are the most-studied chemicals. Chronic treatment with SSRIs upregulates neurogenesis in the DG of the adult hippocampus [2,9], and this increase in neurogenesis seems to exert the antidepressant effects of SSRIs [9]. Increased extracellular serotonin (5-hydroxytryptamine, 5-HT) by SSRIs upregulates neurogenesis by increasing the proliferation of precursor cells [10] and cell survival [11]. 5-HT also gives rise to the upregulation of expression of neurotrophins, such as BDNF, which may stimulate differentiation and the survival of neurons [12]. Additionally, we have shown that fluoxetine (FLX), an SSRI, has the ability to alter the state of dentate granule cells.
Chronic treatment with FLX can drastically reverse the established state of neuronal maturation in adult hippocampal granule cells [13], in a process called “dematuration”, in which the cells display similar features to immature dentate gyrus of the mice heterozygous for the alpha-isofrom of calcium/calmodulin-dependent protein kinase II in gene expression and electrophysiology [14]. It remains unclear whether or not dematuration of mature granule cells provides a therapeutic benefit for major depression and/or for side effects of FLX.

As described above, a considerable number of reports concerning the effects of FLX on hippocampal neurogenesis are available. In contrast, there are only a few reports on the effects of FLX on neurogenesis in the SVZ [2,9,10,15-18]. Almost all of the studies in the literature have revealed no influence of FLX on neurogenesis in the SVZ. In the experiments, the authors administered FLX for 2 to 4 weeks as a chronic treatment model, and the time courses that the authors used in the experiments on neurogenesis in the SVZ were the same as those in the DG [2,9,10,15-18]. Considering that 5-HT-containing fibers and 5-HT receptor subtypes can be detected in the SVZ [19] and that a pharmacological experiment with agonists and antagonists of 5-HT receptor subtypes suggested that 5-HT regulates neurogenesis in the SVZ [19], we hypothesized that FLX has a late-onset effect on neurogenesis in the SVZ. In the present study, to test this hypothesis, we administered FLX into adult mice for up to 9 weeks to examine whether or not FLX treatment affected neurogenesis in the SVZ.

Results

Chronic treatment with FLX has opposite effects on the regulation of cell proliferation in the DG than in the SVZ

Cell proliferation in both the DG and SVZ was determined by immunohistochemical detection of Ki67, a nuclear protein expressed during all phases of the cell cycle, and 5-bromodeoxyuridine (BrdU), a thymidine analogue that is incorporated into DNA during the S-phase of the cell cycle. In the analysis of cell proliferation with BrdU treatment, mice were killed 24 h after a single BrdU injection on each of the last 3 days in each administration period of FLX. (A) For cell proliferation studies, mice were killed 24 h after a single BrdU injection on each of the last 3 days in each administration period of FLX. (B) For neurogenesis studies, mice were killed 3 weeks after days of BrdU injections.

Ki67-positive and BrdU-positive cells were scattered in the subgranular zone and at the bottom of the granule cell layer. Significant increases in the numbers of Ki67-positive (Figure 2C; sham vs. FLX P = 0.00929, control vs. FLX P = 0.00491) and BrdU-positive cells (Figure 3C; sham vs. FLX P = 0.00386, control vs. FLX P = 0.00891) were already detected at 3 weeks. Increased numbers of Ki67-positive and BrdU-positive cells in the DG of mice treated with FLX rose slightly at 6 weeks (Ki67: sham vs. FLX, P = 0.00131, control vs. FLX P = 0.00233; BrdU: sham vs. FLX P = 0.00146, control vs. FLX P = 0.00051) and were sustained up to 9 weeks (Ki67: sham vs. FLX, P = 0.00083, control vs. FLX P = 0.00072; BrdU: sham vs. FLX P = 0.00073, control vs. FLX P = 0.00041). These results were well compatible with the obvious reports demonstrating that FLX’s effect on the proliferation of neural progenitor cells appears by 3 weeks [2,10,11,15,17]. Such alterations of the numbers of Ki67-positive and BrdU-positive cells were not seen in the sham-operated or control pellet-administered mice during the experimental period.

In the SVZ, type-A cells (neuroblasts) are born throughout the SVZ, migrate in chains toward the olfactory bulb, and differentiate into granular or periglomerular interneurons [21]. The chains of type-A cells are ensheathed by type-B cells (SVZ GFAP-positive cells) [22,23]. Some type-B cells have been reported to work as neural stem cells. Type-C cells are clusters of rapidly dividing immature cells on the migration pathway.
Figure 2 Effects of FLX on the numbers of Ki67-positive cells in the DG and the SVZ. (A) Cell proliferation in the DG. Ki67-positive structures, which are the nuclei of proliferating cells, stand in a line between the granule cell layer and the hilus. FLX treatments upregulated Ki67-positive cells in all periods, compared with sham-operated and control pellet-administered mice. (B) Cell proliferation in the SVZ. The numbers of Ki67-positive cells in FLX-treated mice were decreased at 6 and 9 weeks, but not at 3 weeks. The numbers of Ki67-positive cells in the DG (C) and the SVZ (D) are quantified. The values are means ± SEM of 4-5 animals in each group. ** p < 0.01 significantly different from the sham-operated group. Gr, granule cell layer; Hi, hilus; Lv, lateral ventricle; Mo, molecular layer; Se, septum; St, striatum.
Figure 3 Effects of FLX on the numbers of BrdU-positive cells in the DG and the SVZ. (A) BrdU-positive structures, which are the nuclei of proliferating cells and early postmitotic immature granule cells, stand in a line between the granule cell layer and the hilus. FLX treatments upregulated BrdU-positive cells in all periods, compared with sham-operated and control pellet-administered mice. (B) BrdU-positive cells in the SVZ of FLX-treated mice. The numbers of BrdU-positive cells in the DG (C) and the SVZ (D) are quantified. The values are means ± SEM of 4-5 animals in each group. ** p < 0.01 significantly different from sham-operated group. Gr, granule cell layer; Hi, hilus; Lv, lateral ventricle; Mo, molecular layer; Se, septum; St, striatum.
physically located between type-B and type-A cells [23]. Thus, the SVZ neurogenic lineage is type-B cell (stem cell) > type-C cell (progenitor cell) > type-A cell (neuroblast). In this study, labeling of SVZ neurogenesis on the last 3 days before sacrifice can detect type-B and type-C cells located in the SVZ [1]. In addition, type-C cells migrate out from the SVZ. Thus, it is proven that BrdU-positive cells in the SVZ are almost certainly proliferating type-B and type-C cells. Actually, we found that both Ki67-positive (Figure 2B) and BrdU-positive cells (Figure 3B) were uniformly distributed in the SVZ of mice treated with FLX for 3 weeks. However, subtle though insignificant decreases in the numbers of Ki67-positive (Figure 2D; sham vs. FLX P = 0.494, control vs. FLX P = 0.207) and BrdU-positive cells (Figure 3D; sham vs. FLX P = 0.159, control vs. FLX P = 0.255) were observed. Interestingly, unlike the upregulation effect of FLX on cell proliferation in the DG, the treatments of FLX for more than 6 weeks significantly reduced the numbers of Ki67-positive (6 w: sham vs. FLX P = 0.00049, control vs. FLX P = 0.00255; 9 w: sham vs. FLX P = 0.00046, control vs. FLX P = 0.00189) and BrdU-positive cells (Figure 3D; sham vs. FLX P = 0.00301, control vs. FLX P = 0.00179; 9 w: sham vs. FLX P = 0.00012, control vs. FLX P = 0.00111) in the SVZ, suggesting that the abilities of stem cells/progenitor cells to renew themselves and to produce daughter cells were downregulated by the FLX treatments. The downregulation of cell proliferation seemed to take place through the SVZ. Cell proliferation in the dorsal region between the corpus callosum and the striatum was reduced to a similar extent in the ventral region of the SVZ (Figure 2B, 3B).

**Chronic treatment with FLX has opposite effects on neurogenesis between the DG and the SVZ**

The above data indicate that the FLX treatment has opposite effects on cell proliferation between the DG and the SVZ. Next, to determine whether or not the FLX treatment influenced neurogenesis in the DG and the SVZ, new cells were examined if they had survived a 3-week post-BrdU injection period during the FLX treatments for 6 and 9 weeks (Figure 1B). In this analysis, to detect new dentate granule cells, we used a double staining with BrdU and a neuronal marker, NeuN. We selected NeuN because the expression of NeuN is not affected by the FLX treatment [13]. In contrast, a mature granule cell marker, calbindin, has been shown to be greatly reduced by FLX administration [13].

As expected from the above results, in the DG the number of BrdU/NeuN-double-positive cells was significantly increased by 6 and 9 weeks of chronic treatment compared with corresponding sham-operated and control groups (Figure 4; 3-6 w: sham vs. control P = 0.00468, control vs. FLX P = 0.00813; 6-9 w: sham vs. FLX P = 0.00050, control vs. FLX P = 0.00083). We found no difference in the numbers of BrdU/NeuN-double-positive cells between the 3-week period of 3-6 weeks and that of 6-9 weeks of FLX treatment (Figure 4D; 3-6 w vs. 6-9 w P = 0.837). This suggests that FLX’s effect on neurogenesis in the DG reaches a plateau at 3 weeks into FLX treatment.

In the SVZ-olfactory-bulb system, new neurons generated in the SVZ migrate to the olfactory bulb through the rostral migration stream and differentiate into granule cells or periglomerular cells [1]. To determine whether or not FLX treatment affected neurogenesis in the SVZ-olfactory-bulb system, we analyzed the alteration of the number of BrdU/NeuN-double-positive cells in the olfactory bulb. In the 3-week period of 3-6 weeks after FLX administration, we detected few significant changes in the numbers of BrdU/NeuN-double-positive cells in the olfactory bulb (Figure 5A, D; sham vs. FLX P = 0.328, control vs. FLX P = 0.108). In the analysis of mice that had been treated with FLX for 9 weeks and that had received 3-day injections of BrdU at 3 weeks before sacrifice, we found a significant reduction in the number of BrdU/NeuN-double-positive cells (Figure 5B-D; sham vs. FLX P = 0.00654, control vs. FLX P = 0.00264). This result demonstrates that FLX treatment decreases the number of new neurons in the olfactory bulb.

**FLX’s effect on calbindin expression in dentate granule cells**

As shown above, FLX’s effect on neurogenesis in the SVZ was different from that in the DG depending on the duration of FLX treatment. Our group previously showed that chronic treatment with FLX reduces the expression of calbindin in the granule cells of the DG [13,14]. Thus, to examine whether or not FLX administration affects the dematuration of the DG depending on the duration of FLX treatment, we performed an immunohistochemical analysis of calbindin expression in the DG. Similarly depressed expressions of calbindin were clearly observed in the mice treated with FLX for 3, 6, and 9 weeks (Figure 6A). These decreases in calbindin expression were found in all mice treated with FLX for each duration (Figure 6B). These results suggest that FLX’s effect on dematuration on the DG was unrelated to the duration of the treatment periods up to 9 weeks.

**Discussion**

The present findings show that chronic treatment with FLX for more than 6 weeks can reduce cell proliferation in the SVZ, resulting in the downregulation of the number of new neurons in the olfactory bulb. In the DG, on the other hand, FLX treatment consistently increased...
Figure 4 Effects of FLX on the numbers of BrdU- and NeuN-positive cells in the DG. (A) 3-week survival of new neurons in the DG of mice treated with FLX for 6 weeks. (B) 3-week survival of new neurons in the DG of mice treated with FLX for 9 weeks. Tissue sections in both A and B were double-stained with anti-BrdU (green) and anti-NeuN (magenta). The higher magnifications of the boxed-in areas in (B) are displayed in (C). (C) High-power images of BrdU and NeuN double-positive cells (arrowheads) in the DG in the control (top) and FLX-treated mice (bottom). (D) Quantification of BrdU and NeuN double-positive cells in the DG. The values are mean ± SEM of 4-5 animals in each group. ** p < 0.01 significantly different from sham-operated group. Gr, granule cell layer; Hi, hilus; Mo, molecular layer.
cell proliferation and new neurons for up to 9 weeks. These findings suggest that long-term treatment with FLX, such as that lasting more than 6 weeks, has an opposite effect on cell proliferation in the SVZ than it does in the DG.

**Effects of chronic administration of FLX on cell proliferation and neurogenesis**

Our data provided novel evidence that chronic FLX treatment for more than 6 weeks reduced cell proliferation and neurogenesis in the SVZ (Figure 2, 3, 5). The
previous studies treated mice with FLX for time periods ranging from 1 day to 4 weeks, while we medicated mice with FLX for longer periods of up to 9 weeks. This prolonged period is critical for the reduction of cell proliferation and neurogenesis in the SVZ. Currently, the mechanism underlying late-onset reduction of cell proliferation and neurogenesis in the SVZ remains unclear. There are a few possibilities, as follows.

It could be postulated that the expressional changes of 5-HT receptors are a possible mechanism for the
reduction of cell proliferation and neurogenesis in the SVZ during the treatment periods. To date, a number of 5-HT receptors have been identified, and some subtypes may be involved in adult neurogenesis in the SVZ, considering the evidence from pharmacological studies and the expression data of the receptors [24-28]. For example, treatment with ketanserin, a 5-HT2C receptor agonist, increases cell proliferation in the SVZ [19]. In contrast, treatment with sumatriptan, a 5-HT1B receptor agonist, decreases cell proliferation in the SVZ [19].

Thus, FLX-dependent altered and balanced expressions of the 5-HT receptors might become oriented toward the decrease in cell proliferation and neurogenesis in the SVZ. In light of cell proliferation and neurogenesis in the DG, the strong expression of the 5-HT1A receptor may be detected, and 8-hydroxy-2-(di-n-propylamino) tetralin, a 5-HT1A receptor agonist, elevates cell proliferation in the DG [11,19]. Since the expression level of the 5-HT1A receptor in the hippocampus cannot be altered by 3 weeks of FLX treatment [29], the stable enhancement of cell proliferation and neurogenesis may be detected in the DG. Thus, there is a difference in response to 5-HT between neural stem cells and progenitor cells in the DG and the SVZ, and the difference may be based on the expressions of 5-HT receptors.

Another possibility is the direct actions of FLX to nicotinic acetylcholine receptors (nAChRs). FLX has been shown to be an antagonist of nAChRs [30]. nAChRs play important roles in the enhancement of cell proliferation of neural stem cells and precursor cells [31]. Interestingly, the administration of nicotine increases cell proliferation in the SVZ of adult rats but not in the DG, and this effect is mediated by the induction of FGF-2 [32]. In contrast to the role of FGF-2 on cell proliferation in the SVZ, the apparent absence of an FGF-2 effect in the DG has been reported [33]. Thus, FLX treatments decrease FGF-2 expression via the inhibition of nAChRs, which may result in the reduction of cell proliferation and neurogenesis in the SVZ.

The possibility of mechanisms other than those described above cannot be excluded, and further study will be necessary to determine the mechanisms underlying the delayed reduction of cell proliferation neurogenesis in the SVZ.

**Implications of FLX treatment for depression**

Citalopram, an SSRI, and clomipramine, a tricyclic antidepressant, induces a decrease in olfactory sensitivity after 3 weeks of treatment in mice [34]. The antidepressant rolipram, a monoamine oxidase inhibitor, is shown to impair the accuracy of mice in detecting odorants [35]. Considering that there is a positive correlation between the loss of olfactory function and reduced olfactory bulb volume [36,37], the loss of olfactory functions by treatment with antidepressants might be attributable to the reduction in new neurons in the olfactory bulb, which in turn is due to the decreases in both cell proliferation and neurogenesis in the SVZ. Also, some of the side effects of antidepressants might be mediated by decreased adult neurogenesis in the SVZ. A recent human case study showing that patients with major depression detect an unfavorable and intolerable smell about 7 weeks after the administration of citalopram may be related to the decrease in new neurons of the olfactory bulb [38]. In the animal models whose neurogenesis in the SVZ is ablated, it is found that the animals display a diminished behavioral fear response to conditioned odor cues [39], but their olfactory discrimination and long-term olfactory memory are not affected [39-41].

These data suggest that the decrease in neurogenesis in the SVZ might affect the emotional behaviors of animals via functional alterations of the circuits of the central nervous system as well as the olfactory bulb. The olfactory system forms a part of the limbic region that contributes to the emotional and memory components of animal behaviors. These areas, the frontal cortex-hippocampus-amygdala circuit, also seem to be dysfunctional in patients with major depression [42,43]. The olfactory bulb sends inhibitory projections to the amygdala, which is involved in the processing of emotion, such as fear, sadness, and aggression [44]. Dysfunction of the olfactory bulb might not only reduce olfactory sensitivity but also increase fear, sadness, and aggression by disinhibiting the amygdala [45,46]. Moreover, treatments with SSRIs seem to be a cause of aggression and violence as side effects [47]. The reduction of neurogenesis in the SVZ, which is shown in the present study, might be associated with certain side effects of SSRIs. Alternatively, the decrease in adult neurogenesis in the SVZ also might be involved in the therapeutic effects of SSRIs on major depression. The olfactory bulb-ablated animals have been reported to show markedly increased exploratory behaviors, such as ambulation and rearing [48], and spend significantly more time exploring a novel object into the center of the open field [49], suggesting that the reduced function of olfactory bulb may decrease the anxiety of the animals. Further researches are needed to clarify the functional and behavioural significances of the reduced SVZ adult neurogenesis caused by the chronic treatment of FLX.

There is a straightforward relationship between FLX treatment and the reduction of cell proliferation and neurogenesis in the SVZ of animals in healthy condition. However, there is a discrepancy in treatments with antidepressants to animal models of major depression. Bulbectomized rats, an animal model of major depression, have shown significant decreases in cell proliferation...
and neurogenesis in both the DG and the SVZ [50]. Contrary to the expectation that cell proliferation and neurogenesis would decrease by FLX treatment in depression model animals, treatment with imipramine, a tricyclic antidepressant, for 15 days normalized the reduction of neurogenesis in the SVZ in bulbectomized rats [50]. Furthermore, although chronic stress, which can induce the onset of major depression, decreased the number of neural stem cells in the SVZ of adult mice, FLX treatment for 3 weeks reverses the decrease in the number of neural stem cells in the SVZ [51]. These reports suggest that quite opposite phenomena occur in depression model animals medicated with FLX compared with healthy control animals administered FLX. Although the mechanism that explains these discrepancies is unclear at present, we can speculate on two possibilities: 1) the alterations in the sensitivities of neural stem cells in the SVZ to 5-HT, containing functional and expressional changes of 5-HT receptors, transporters, and 5-HT signal transduction pathways; and 2) the direct influence of FLX on neural stem cells and progenitor cells, such as expressional changes of nAChRs in neural stem cells and progenitor cells. Such alterations might explain the different effects of antidepressants between control and model animals and also between major depression patients and healthy subjects.

Conclusions
We have provided the first evidence for the FLX-dependent decrease in adult neurogenesis in the SVZ. The reduction in neurogenesis in the SVZ by FLX treatment might be involved in some of the therapeutic effects on depression and side-effects of FLX, such as aggression and violence.

Methods
Antidepressant treatment
Adult male C57BL/6J mice (4-5 mice for each group and each time point; Charles River Laboratories, Japan, Inc., Shiga, Japan), which were 8 weeks old at the start of the experiments, were used for all of the experiments. All animal experiments were approved by the Institutional Animal Care and Use Committee of Fujita Health University, based on the Law for the Humane Treatment and Management of Animals (2005) and the Standards Relating to the Care and Management of Laboratory Animals and Relief of Pain (2006). Every effort was made to minimize the number of animals used. Animals were group-housed (12 h light/dark cycle) with free access to food and water. After 1 week of habituation to mouse cages, the mice were subcutaneously administered either an antidepressant or vehicle pellets (Innovative Research of America, Sarasota, FL) in the dorsal interscapular region of mice [52,53]. The drug pellets contained 7.245 mg and 20.7 mg of fluoxetine; these dosages were calculated so that a mouse with a body weight of 23 g received fluoxetine at 15 mg/kg/day for 21 days and 60 days, respectively (Figure 1). We have chosen the concentration of FLX, since serum FLX levels in mice receiving 15 mg/kg/day chronic FLX have been shown to be comparable to those in human patients receiving 20-80 mg FLX (Prozac) per day [54]. The pellets without fluoxetine were administered to mice designated as control mice. In addition, sham-operated mice, which were operated on but did not receive any pellets, were used.

Since the mice that we used were 8 weeks old at the start of the experiments, their body weight increased during the experiments. We then determined the actual dose of FLX corrected for body weight after 9 weeks of FLX treatment. The body weight in each group was as follows: sham-operated mice, 27.8 ± 0.317 g (n = 5); control pellet-administered mice, 27.3 ± 0.521 g (n = 5); FLX pellet-administered mice, 26.7 ± 0.850 g (n = 5). Using these data, we calculated the actual dose of FLX as described below, 1000 g/[body weight (g) after 9 weeks of FLX treatment] × 0.345 mg (amount of FLX released from the 60-day pellet/day) = 13.0 ± 0.407 mg/kg/day. This value was within the plasma FLX levels for patients taking 20-80 mg Prozac per day [54].

BrdU labeling
BrdU (Sigma, St. Louis, MO) stock solution was prepared in phosphate-buffered saline (PBS), (pH 7.2, 0.1 M) with 0.007 N NaOH at 20 mg/ml. After a certain period, the animals were injected intraperitoneally with BrdU (100 mg/kg body weight) every 24 h for 3 days to label newborn neurons (Figure 1).

Immunohistological analysis
Mice were deeply anesthetized and transcardially perfused with 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. The brains were dissected, immersed overnight in the same fixative, and transferred to 30% sucrose in PBS, containing sodium azide (0.05%, w/v) at 4°C until use. Brain samples were mounted in Tissue-Tek (Miles, Elkhart, IN), frozen, and cut into 50-μm-thick coronal sections using a microtome (CM1850, Leica Microsystems, Wetzlar, Germany). Sections were stored in PBS containing sodium azide (0.05%, w/v) at 4°C until use.

For BrdU staining, sections were incubated at 4°C for 10 min in 0.1 N HCl and then at 37°C for 30 min in 2 N HCl. Sections were washed twice for 5 min in PBS and then blocked in 0.2 M glycine in PBS at room temperature for at least 2 h. After washing in PBS for 1 h, all sections were preincubated with PBS-DB (4% normal donkey serum [Vector Laboratories, Burlingame, CA] and 1% BSA in PBS) for 2 h at room temperature. The sections were
incubated at 4°C for 48 h or at room temperature overnight with the indicated primary antibodies. We used the following primary antibodies: mouse monoclonal anti-Ki-67 (1:20; BD Pharmingen, Franklin Lakes, NJ), mouse monoclonal anti-NeuN (1:200; Millipore, Billerica, MA), and rat monoclonal anti-BrdU (1:100; Abcam, Cambridge, UK). After washing in PBS for 1 h, the sections were incubated at room temperature for 1 h with the following secondary antibodies: anti-mouse IgG Alexa 488 (1:200; Molecular Probes, Eugene, OR), anti-rat IgG Alexa 594 (1:200; Molecular Probes). After washing in PBS containing Hoechst 33258 for nuclear counterstaining for 1 h, the sections were mounted on glass slides coated with 3-aminopropyltriethoxysilane and embedded with Permafluor (Thermo Shandon, Pittsburgh, PA). We used a confocal laser-scanning microscope (LSM 700; Carl Zeiss, Germany) to obtain images of the stained sections.

Quantification of labeled cells

A quantification analysis was performed as reported previously [55]. Briefly, analysis was performed using a confocal microscope equipped with a 40× objective lens (Plan-NEOFLUAR, NA = 0.75, Carl Zeiss) and a pinhole setting that corresponded to a focal plane thickness of less than 1 μm. To exclude false-positives due to the overlay of signals from different cells, randomly selected positive cells were analyzed by moving through the entire z-axis of each cell. Cells were counted under the live mode of confocal scanning. Data were analyzed by one-way ANOVA and then by Scheffe’s post hoc test. Error bars represent SEM.

List of abbreviations

BrdU: 5-bromodeoxyuridine; DG: dentate gyrus; Ex: external plexiform layer; FLX: fluoxetine; GM: glomerular layer; GCL: granule cell layer; Hi: hilus; 5-HT: 5-hydroxytryptamine; Lv: lateral ventricle; Mo: molecular layer; nAChR: nicotinic acetylcholine receptor; Se: septum; SBR: selective serotonin reuptake inhibitor; St: stratum; SV: subependymal zone; SVZ: subventricular zone

Acknowledgements and funding

The authors thank Drs Gordon Murphy and James Harrison for their critical reading of the manuscript and Ms Satoko Noma for technical assistance. This work was supported by a Grant-in-Aid for Scientific Research on Priority Area ‘Pathomechanisms of Brain Disorders’ (20023017) and by a Grant-in-Aid for Young Scientists B (21700384) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan, as well as by grants from CREST of the Japan Science and Technology Agency (JST).

Author details

1Division of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Japan. 2Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Kawaguchi, Japan. 3Section of Behavior Patterns, Center for Genetic Analysis of Behavior, National Institute for Physiological Sciences, Okazaki, Japan.

Authors’ contributions

TM designed the study and wrote the manuscript. KO participated in the design of the study, carried out all the experiments, and co-wrote the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 19 January 2011 Accepted: 8 March 2011 Published: 8 March 2011

References

1. Zhao C, Deng W, Gage FH: Mechanisms and functional implications of adult neurogenesis. Cell 2008, 132:645-660.
2. Malberg JE, Eisich AJ, Nestler EJ, Duman RS: Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000, 20:9104-9110.
3. Fabel K, Fabel K, Tam B, Kaufe D, Bailer A, Simmons N, Kuo CJ, Palmer TD: VEGF is necessary for exercise-induced adult hippocampal neurogenesis. Eur J Neurosci 2003, 18:2803-2812.
4. Kempermann G, Gage FH: Experience-dependent regulation of adult hippocampal neurogenesis: effects of long-term stimulation and stimulus withdrawal. Hippocampus 1999, 9:321-332.
5. Shingo T, Gregg C, Envero E, Fukushima H, Yasuda S, Geary C, Cross JC, Weiss S: Pregnancy-stimulated neurogenesis in the adult female forebrain mediated by prolactin. Science 2003, 299:117-120.
6. Jin K, Minami M, Lan JQ, Mao XO, Batteur S, Simon RP, Greenberg DA: Neurogenesis in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia in the rat. Proc Natl Acad Sci USA 2001, 98:4710-4715.
7. Gould E, McGwen BS, Tanapat P, Galea LA, Fuchs E: Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation. J Neurosci 1997, 17:2492-2498.
8. Seki T, Arai Y: Age-related production of new granule cells in the adult dentate gyrus. Neuroreport 1995, 6:2479-2482.
9. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R: Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
10. Encinas JM, Vahtokari A, Enkoolpov G: Fluoxetine targets early progenitor cells in the adult brain. Proc Natl Acad Sci USA 2006, 103:8233-8238.
11. Klempin F, Babu H, Tonelli DDP, Alarcon E, Fabel K, Kempermann G: Opppositional Effects of Serotonin Receptors 5-HT1A, 2, and 2c in the Regulation of Adult Hippocampal Neurogenesis. Front Mol Neurosci 2010, 3.
12. Mattson MP, Maurisly S, Martin B: BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2004, 27:589-594.
13. Kobayashi K, Ikeda Y, Sakai A, Yamazaki N, Haneda E, Miya-Kawa T, Suzuki H: Reversal of hippocampal neuronal maturation by serotonergic antidepressants. Proc Natl Acad Sci USA 2010, 107:8434-8439.
14. Yamazaki N, Mae-Kawa M, Kobayashi K, Kaji Y, Maeda J, Soma M, Takao K, Tanda K, Ohira K, Toyama K, Kanzaki K, Fukunaga K, Sudo Y, Ichinose H, Ikeda M, Izawa N, Ozaki N, Suzuki H, Higuchi M, Suhara T, Yuasa S, Miyakawa T: Alpha-CaMKII deficiency causes immature dentate gyrus, a novel candidate endophenotype of psychiatric disorders. Mol Brain 2008, 1:6.
15. Kodama M, Fujitoka T, Duman RS: Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 2004, 56:570-579.
16. Surget A, Saxe M, Leman S, Ibarquen-Vargas Y, Chalon S, Griebel G, Hen R, Belzung C: Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol Psychiatry 2008, 64:293-301.
17. Hodges GE, Hill-Smith TE, Suckow RF, Cooper TB, Lucki I: Sex-specific effects of chronic Fluoxetine treatment on neuroplasticity and pharmacokinetics in mice. J Pharmacol Exp Ther 2010, 332:266-273.
18. Nasrallah HA, Hopkins T, Pickel SK: Differential effects of antidepressant drugs on neurogenic regions in rats. Brain Res 2010, 1354:25-29.
19. Banasar M, Hery M, Prenterps R, Dazsa A: Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology 2004, 29:450-460.
20. Song H, Stevens CF, Gage FH: Astroglia induce neurogenesis from adult neural stem cells. Nature 2002, 417:39-44.

21. Doetsch F, Alvarez-Buylla A: Network of tangential pathways for neuronal migration in adult mammalian brain. Proc Natl Acad Sci USA 1996, 93:14995-14999.

22. Lois C, Garcia-Verdugo JM, Alvarez-Buylla A: Chain migration of neuronal precursors. Science 1996, 271:978-981.

23. Doetsch F, Garcia-Verdugo JM, Alvarez-Buylla A: Cellular composition and three-dimensional organization of the subventricular germinal zone in the adult mammalian brain. J Neurosci 1997, 17:5046-5061.

24. Francis PT, Pangalos MN, Pearson RC, Middelms DN, Stammann GC, Bowen DM: 5-Hydroxytryptamine1A but not 5-hydroxytryptamine2 receptors are enriched on neocortical pyramidal neurons destroyed by intrastriatal voltensin. J Pharmacol Exp Ther 1992, 261:1273-1281.

25. Bruinvels AT, Landwehrmeyer B, Gustafson EL, Durkin MM, Mengod G, Brancheck TA, Hoyer D, Palacios JM: Localization of 5-HT1B, 5-HT1 D alpha, 5-HT1F and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropharmacology 1994, 33:367-386.

26. Laporte AM, Lima L, Gostan H, Hamon M: Selective in vivo labelling of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse. Eur J Pharmacol 1994, 271:505-514.

27. Abramowski D, Rigo M, Duc D, Hoyer D, Staufenbiel M: Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera. Neuropharmacology 1995, 34:1635-1645.

28. Wright DE, Seroogy KB, Lundgren KH, Davis BM, Jennes L: Specific antisera. Neuropharmacology 1995, 271:227-237.

29. Costa-Freda SG, Baramer MJ, David AS, Fu CHY: Selective in vivo labelling of 5-HT1B, 5-HT1 D alpha, 5-HT1F and 5-HT1F receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuropharmacology 2000, 39:110-122.

30. Garcia-Colunga J, Awad JN, Miledi R: Neuropharmacology of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse brain. Neuropharmacology 1994, 271:227-237.

31. Resende RR, Adhikari A: Cholinergic receptor pathways involved in apoptosis, cell proliferation and neuronal differentiation. Cell Commun Signal 2009, 7:20.

32. Mudd G, Belluardo N, Mauro A, Fuxe K: Acute intermittent nicotine treatment induces fibroblast growth factor-2 in the subventricular zone of the adult rat brain and enhances neuronal precursor cell proliferation. Neuroscience 2007, 145:470-483.

33. Kuhn HG, Wendler M, Rudigier KH, Davis BM, Jennies L: Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain. J Comp Neurol 1995, 351:357-373.

34. Le Poul E, Boni C, Hanour N, Laporte AM, Laaris N, Chaveau J, Hamon M, Lanfumey L: Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuropharmacology 2000, 39:110-122.

35. García-Colunga J, Awad JN, Miledi R: Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc Natl Acad Sci USA 1997, 94:2041-2044.

36. Resende RR, Adhikari A: Cholinergic receptor pathways involved in apoptosis, cell proliferation and neuronal differentiation. Cell Commun Signal 2009, 7:20.

37. Pho V, Butman ML, Cherry JA: Type 4 phosphodiesterase inhibition impairs detection of low odor concentrations in mice. Behav Brain Res 2005, 161:245-253.

38. Mueller A, Rodewald A, Reden J, Gerber J, von Kummer R, Hummel T: Reduced olfactory bulb volume in post-traumatic and post-infectious olfactory dysfunction. Neuropsychiatr 2005, 3:475-478.

39. Bormbaux P, Kikka M, Benmouz A, Bertrand B, Nicolas G, Duprez T, Hummel T: Retronasal and orthonasal olfactory function in relation to olfactory bulb volume in patients with posttraumatic loss of smell. Laryngoscope 2006, 116:901-905.

40. Ghaniadeh A: Unfavorable smell with citalopram? J Clin Psychopharmacol 2007, 27:528-529.

41. Breton-Provencher V, Lemasson M, Peralta MR, Saghatelyan A: Interneurons produced in adulthood are required for the normal functioning of the olfactory bulb network and for the execution of selected olfactory behaviors. J Neurosci 2009, 29:15245-15257.

42. Baxter LR, Schwartz JM, Phelps ME, Mazzotta JC, Guze BH, Selin CE, Gerber RH, Surnick RM: Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 1989, 46:243-250.

43. Nestler EJ, Barrot M, DiLeone RJ, Ichs AI, Gold SJ, Monteggia LM: Neurobiology of depression. Neuron 2002, 34:13-25.

44. Scottafreada SG, Baramer MJ, David AS, Fu CHY: Predictors of amygdala activation during the processing of emotional stimuli: a meta-analysis of 385 PET and fMRI studies. Brain Res Rev 2008, 58:57-70.

45. Huchou H, Ho Y, Shiu H, Tai M, Chen KS, Tsai Y: Effects of incisor-cutting on masticatory behavior induced by olfactory bulbectomy in rats. Physiol Behav 2002, 76:669-675.

46. Mucignat-Caretta C, Bondi M, Caretta T: Time course of alterations after olfactory bulbectomy in mice. Physiology & Behavior 2006, 89:637-643.

47. Healy D, Heinheimer A, Menkes DR: Antidepressants and violence: problems at the interface of medicine and law. Plas Med 2006, 3:637.

48. Ueki S, Nunimoto S, Ogawa N: Characteristics in Emotional Behavior of the Rat with Bilateral Olfactory Bulb Ablations. Psychiatri Clin Neurosci 1972, 27:142-157.

49. Zueger M, Urani A, Chourbai S, Zacher C, Roche M, Harkin A, Gass P: Olfactory bulbectomy in mice induces alterations in exploratory behavior. Neurosci Lett 2005, 374:142-146.

50. Keilhoff G, Becker A, Grecksch G, Bernstein H, Wolf G: Cell proliferation is influenced by bulbectomy and normalized by imipramine treatment in a region-specific manner. Neuropharmacology 2006, 31:1165-1176.

51. Hitoshi S, Maruta N, Higashi M, Kumar A, Kato N, Ikenaka K: Antidepressant drugs reverse the loss of adult neural stem cells following chronic stress. J Neurosci Res 2005, 85:3574-3585.

52. Covington HE, Maze I, Laplant QC, Valouf W, Ohnishi YN, Berton O, Fass DM, Renthal W, Rush AJ, Wu EY, Ghose S, Krishnan V, Russo SJ, Tamminga C, Haggarty SJ, Nestler EJ: Antidepressant actions of histone deacetylase inhibitors. J Neurosci 2009, 29:11451-11460.

53. Vialou V, Robison AJ, Laplant QC, Covington HE, Dietz DM, Ohnishi YN, Mouzon E, Rush AJ, Watts EL, Wallace DL, Higuez SD, Ohnishi H, Steiner MA, Warren BL, Krishnan V, Bofano CA, Neve RL, Ghose S, Berton O, Tamminga CA, Nestler EJ, DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses. Nat Neurosci 2010, 13:745-752.

54. Dulawa SC, Holka K, Gundersen B, Hen R: Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropharmacology 2004, 29:1321-1330.

55. Ohira K, Higahara Y, Toyama K, Takao K, Kani M, Funakoshi H, Nakamura T, Miyakawa T: Expression of tryptophan 2,3-dioxygenase in mature granule cells of the adult mouse dentate gyrus. Mol Brain 2010, 3:26.

Cite this article as: Ohira and Miyakawa: Chronic treatment with fluoxetine for more than 6 weeks decreases neurogenesis in the subventricular zone of adult mice. Molecular Brain 2011; 4:10.